Muhammad Athar, MD
Pulmonary Disease · North Chesterfield, VANPI 1063673606
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.9%), grants and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Intuitive Surgical at 54.0% of the total. Reporting peaked in 2023 at $13,324 and has fallen 95.6% since, to $581 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $318.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- Medtronic$10K
- GSK$282
- Abbott$220
- AstraZeneca$121
- Amgen$94
- plus $539 from 15 others
What the payments were for
- Grants$10,00041%
- Travel & lodging$1,1875%
- Food & beverage$1,3536%
- Education$12,00049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $13,256 |
| Medtronic(2 entities) | 3 | $10,028 |
| GSK | 21 | $282 |
| Abbott | 2 | $220 |
| AstraZeneca | 7 | $121 |
| Amgen | 5 | $94 |
| Grifols USA, LLC | 4 | $80 |
| Sanofi | 3 | $62 |
| Boehringer Ingelheim | 3 | $57 |
| Vifor Pharma, Inc. | 3 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Novartis | 2 | $37 |
| Philips North America LLC | 2 | $31 |
| United Therapeutics Corporation | 2 | $29 |
| Pfizer | 1 | $27 |
| Atricure, Inc. | 1 | $26 |
| Insmed, Inc. | 2 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$10,168
- ION$3,000
- ENSITE PRECISION$187
How this compares
$24,540 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 368 | $278,050 |
| Breo ElliptaFluticasone/Vilanterol | 301 | $142,933 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 116 | $98,633 |
| Spiriva RespimatTiotropium Bromide | 110 | $93,688 |
| SymbicortBudesonide/Formoterol Fumarate | 186 | $58,981 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $25,521 |
| EliquisApixaban | 38 | $20,809 |
| Advair HfaFluticasone Propion/Salmeterol | 43 | $17,214 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $13,886 |
| Ambrisentan | 11 | $13,668 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 117 | $13,002 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 513 | $12,498 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $12,497 |
| Arnuity ElliptaFluticasone Furoate | 45 | $11,052 |
| Spiriva HandihalerTiotropium Bromide | 14 | $9,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $282 | $458,418766 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $121 | $157,615302 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $57 | $119,209152 claims |
| PfizerEliquis | $27 | $20,80938 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $8,31226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in North Chesterfield
- Adam KaiserNorth Chesterfield$67K
- Alice HerlihyNorth Chesterfield$18K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.